Distinguished in Anal Cancer

Dr. Aparna R. Parikh

Oncology
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
Offers Telehealth
17 Years of Experience
Distinguished in Anal Cancer
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Aparna Parikh is an Oncologist in Boston, Massachusetts. Dr. Parikh has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Anal Cancer. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Tissue Biopsy.

Her clinical research consists of co-authoring 135 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 8 articles in the study of Anal Cancer.

Graduate Institution
Indiana University School Of Medicine, 2005 - 2009, 2009
Residency
Massachusetts General Hospital, 2009 - 2012
Specialties
Oncology
Licenses
Internal Medicine in MA
Board Certifications
Medical Oncology
Fellowships
UC San Francisco Medical Center, 2012 - 2014
Hospital Affiliations
Massachusetts General Hospital
North Shore Medical Center -
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

THE GENERAL HOSPITAL CORPORATION
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: January 27, 2026
Intervention Type: Drug
Study Drugs: Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
Study Phase: Phase 1
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: June 06, 2024
Intervention Type: Drug
Study Drug: Lamivudine
Study Phase: Phase 2
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Once Weekly for 4 Weeks to Patients With Advanced Solid Tumors
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Once Weekly for 4 Weeks to Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Phase: Phase 1
Tumor Markers, Liquid Biopsies, and Patient Reported Outcomes in Metastatic Colorectal, Pancreas, Biliary, and Esophagogastric Cancers
Tumor Markers, Liquid Biopsies, and Patient Reported Outcomes in Metastatic Colorectal, Pancreas, Biliary, and Esophagogastric Cancers
Enrollment Status: Completed
Publish Date: August 04, 2022
Intervention Type: Behavioral
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

135 Total Publications

Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators.
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators.
Journal: Cancer discovery
Published: October 07, 2025
Similar Doctors
Elite in Anal Cancer
Dr. Jill N. Allen
Oncology
Elite in Anal Cancer
Dr. Jill N. Allen
Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jill Allen is an Oncologist in Boston, Massachusetts. Dr. Allen is rated as an Elite provider by MediFind in the treatment of Anal Cancer. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Anal Cancer, Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Allen is currently accepting new patients.

Jessica A. Zerillo
Distinguished in Anal Cancer
Dr. Jessica A. Zerillo
Internal Medicine | Oncology
Distinguished in Anal Cancer
Dr. Jessica A. Zerillo
Internal Medicine | Oncology

Beth Israel Deaconess Medical Center - GI Medical Oncology

330 Brookline Avenue, Shapiro 9, 
Boston, MA 
 (2.5 miles away)
617-667-2100
Experience:
17+ years
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Jessica Zerillo is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Zerillo has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Anal Cancer. Her top areas of expertise are Anal Cancer, Familial Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Pancreatic Cancer.

Distinguished in Anal Cancer
Dr. Lawrence S. Blaszkowsky
Oncology | Hematology
Distinguished in Anal Cancer
Dr. Lawrence S. Blaszkowsky
Oncology | Hematology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lawrence Blaszkowsky is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Blaszkowsky is rated as an Elite provider by MediFind in the treatment of Anal Cancer. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parikh's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile